Pharmacia and Upjohn
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Pharmacia and Upjohn sits in the top decile of US sponsors by registered trial count (#1,226 of 15,751 sponsors by registered trial count).
Pharmacia and Upjohn: 11 sponsored US clinical trials, none currently recruiting.
Pharmacia and Upjohn sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 2 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV Infections, with 2 trials.
Top-decile sponsor footprint
Pharmacia and Upjohn ranks in the top decile of sponsors by registered trial count (#1,226 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
11 total, page 1 of 1
A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies
NCT00002210
Safety and Effectiveness of Giving Combinations of Three or Four Anti-HIV Drugs to HIV-Infected Patients
NCT00002211
A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
NCT00002236
The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine
NCT00002312
A Study of Different Doses of Atevirdine Mesylate Plus Zidovudine in HIV-Positive Patients
NCT00002322
A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients
NCT00002400
A Double-Blind, Randomized, Comparative Study of Delavirdine Mesylate (U-90152S) in Combination With Didanosine (ddI) Versus ddI Alone in HIV-1 Infected Individuals With CD4 Counts of <= 300/mm3
NCT00002123
Prospective Open-Label Study of the Emergence of Drug Resistance in Patients Infected With HIV-1 Who Are Taking Oral U-87201E
NCT00002094
A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients
NCT00002401
A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3
NCT00002124
Safety, Tolerance, Efficacy and Pharmacokinetics of Multiple Doses of sCD4-PE40 in the Treatment of HIV-Infected Individuals
NCT00002087
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Phase 3 | 2 |
Therapeutic Areas
How the Pharmacia and Upjohn archive is shaped
11 indexed studies, none listed as recruiting (0% open); 11 completed (100%).
Phase mix: 2 late (III/IV) vs 3 early (I/II) (balanced across stages).
Top condition: HIV Infections (2 trials), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.